Life Biosciences Secures $80 Million in Funding to Advance ER-100 Gene Therapy for Ophthalmic Diseases
Life Biosciences
Drug Developer
▲May 14-15Shanghai Life BiosciencesInnovators SummitScan to Register
Note:This article does not constitute any investment opinions or suggestions; please refer to official/company announcements for accuracy.This article only introduces drugs related to medical health, not a recommendation of treatment options (if involved), and does not represent the platform's position.Reproduction of any article requires authorization.
PharmaCircleMonitoring Shows: Recently, on April 8, Life Biosciences, Inc. ("Life Bio") announced the completion of an $80 million fully subscribed financing. The proceeds from this financing will support the company's operations until the second half of 2027, including the completion of the recently initiated Phase I clinical trial of ER-100, as well as the continued advancement of its broad-spectrum Partial Epigenetic Reprogramming (PER) platform across multiple therapeutic areas.
"Jerry McLaughlin, CEO of Life Biosciences, stated: 'The strong demand for this financing round has been highly encouraging, reflecting the growing market attention on our platform and our potential to reverse a variety of age-related diseases. This funding will advance our core program, ER-100, toward key clinical milestones while continuing to expand our R&D pipeline, enabling Life Bio to provide patients with transformative disease-modifying therapies.'"
Life Bio's PER platform partially reprograms the epigenome of aging and damaged cells by expressing three transcription factors: OCT4, SOX2, and KLF4 (OSK), restoring them to a younger and healthier state. This strategy targets the root causes of aging at the epigenetic level and is expected to have therapeutic effects on various aging-related diseases across multiple organs and systems.
The Phase Ⅰ clinical trial (NCT07290244) conducted by Life Biosciences will evaluate the safety and tolerability of ER-100 in patients with open-angle glaucoma (OAG) and non-arteritic anterior ischemic optic neuropathy (NAION), while also assessing efficacy, including multiple visual function indicators.Optic neuropathies such as OAG and NAION are characterized by the core pathological feature of retinal ganglion cell (RGC) damage, which are the primary neurons connecting the eye to the brain. As retinal ganglion cells cannot naturally regenerate, their damage results in permanent vision loss.
References:
PharmaCircle Data;
Moxie Pharma pharma.bcpmdata.com (formerly Yaorong Cloud Data);
http://www.marketscreener.com；
https://www.businesswire.com；
www1.hkexnews.hk/；
https://www.biotechtv.com/post；
; etc.
